5 results
425
CELG
Celgene Corporation
25 Mar 19
Business combination disclosure
5:25pm
with 57% BMS I-O share Despite Competitive Intensity, BMS Continues to Lead in Key Tumors Where Opdivo is Approved … BMS Has Maintained I-O Leadership
425
CELG
Celgene Corporation
19 Mar 19
Business combination disclosure
7:04am
Hepatocellular Carcinoma 2L Leadership with 57% BMS I-O share Despite Competitive Intensity, BMS Continues to Lead in Key Tumors Where Opdivo … I-O share Head & Neck Post platinum 18% BMS I-O share 2L Hepatocellular Carcinoma 2L Leadership with 57% BMS I-O share Despite Competitive Intensity
425
CELG
Celgene Corporation
6 Mar 19
Business combination disclosure
7:03am
% BMS I-O share Despite Competitive Intensity, BMS Continues to Lead in Key Tumors where Opdivo is Approved 6 Approved PD(L)1s with a Combined43
- Prev
- 1
- Next